Dealing with the Emotions of Hepatitis C

Many people when they are first diagnosed with the Hepatitis C virus, also known as HCV, go through several emotional states. They are frequently angry, wanting to know why such a terrible illness has befallen them. Asking the question of what did they do to deserve such a fate. They are also scared, believing that their lives will never be the same.  They fear loneliness and an early demise. The questions they ask and the frustrations that they feel are very common initial reactions to this terrible news.  These are powerful emotions that need to be dealt with. Hepatitis C sufferers must take care of their emotional needs as well as work to keep their health.

One thing that can help is talking. It really is unhealthy to keep it all inside. Sometimes the best way to get the frustration and fear out is by seeing a councilor. One on one therapy is good for some people. There will be councilors who specialize in patients who are dealing with life threatening illnesses as a part of their normal practice. Others may prefer going to group therapy to have the opportunity to talk to others in similar circumstances. Most councilors have group sessions where people with similar needs will meet regularly to talk out their pain. These sessions can occur weekly or more often if the need is there. 

 There are also often meetings of groups of people, minus the councilor, who get together at community centers or storefronts to share their concerns and questions with others who have the same problems as they do.  There will likely be a group like this that meets to talk about living with Hepatitis. These meetings are also very useful as people with the same problems share ideas on treatments or on how to cope with family and friends now that they know they have the Hepatitis C virus.

Some people prefer anonymity when discussing private issues. They may therefore prefer to use chat rooms on the Internet.  There are so many of these available for any kind of illness one may have. People can talk to others from around the world; learn about what other people do to keep their spirits up. They can compare treatment options and see what success others have had using different drug programs. They may want to discuss other issues like diet or relationships to help understand better how to deal with their lives. Or maybe they are just feeling lonely and want to talk to people who may be able to understand their feelings better than those who may not be experiencing the same set of worries that they are.

Whichever route the person with Hepatitis C should choose, they should remember that they are not alone. Family will not desert them because of their illness and friends will not walk away. The people they have been close to before will also be there to listen and give comfort.  They can still be emotionally involved with people.

Hepatitis news on the Web

As death nears, hepatitis C victim to give videotaped deposition in Desai case - Las Vegas Review-Journal

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience - Wall Street Journal

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes

all 24 news articles »

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ... - FierceBiotech

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

Gilead Sciences Jumps on Hepatitis C Data - Pharmaceutical Processing

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Gilead stock rises on potential hepatitis C cureSan Francisco Business Times (blog)
Proactive Investors USA & Canada -Seeking Alpha -CNBC.com
all 12 news articles »

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover - BusinessWeek

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Up 6% After Positive Hep-C TrialWall St. Cheat Sheet
DailyFinance -24/7 Wall St.
all 63 news articles »

Culture: Impact of war on language (155) - Egyptian Gazette

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

Idenix gets good news on hep C trial, but can't compete with Gilead - FierceBiotech

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech
Idenix put out the news this morning that the FDA had lifted a partial hold on its hepatitis C drug IDX184--and then watched its share price slide. In a sign of just how volatile the whole hepatitis C arena has become after back-to-back blockbuster ...
Idenix Falls Casualty to Gilead Hep C HooplaTheStreet.com
Idenix: FDA lifts partial hold on hepatitis C drugMarketWatch
Idenix Says FDA Lifts Partial Hold On Hepatitis Drug IDX184; But Stock DownNASDAQ
PR Newswire (press release)
all 31 news articles »

Vertex Hep C Sales Growth Nears End - TheStreet.com

Vertex Hep C Sales Growth Nears End
TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
Vertex Falls as Analyst Cuts Hep C Sales Estimate: Boston MoverBusinessWeek
Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C PillBloomberg
Vertex shares drop as analyst cools on high-flying hep C drugBoston Business Journal
LocalizedUSA -Financial News Network Online
all 15 news articles »

Hepatitis Research May Benefit From Stem Cells - Medical News Today

MD News

Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge

all 5 news articles »

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ... - Gastroenterology & Endoscopy News

Gastroenterology & Endoscopy News

New Study of Interferon-free HCV Therapy Hailed as 'Watershed Moment' in Hep C ...
Gastroenterology & Endoscopy News
by Christina Frangou A combination therapy including two investigational direct-acting antiviral agents (DAAs)—asunaprevir and daclatasvir—suppressed hepatitis C virus (HCV) genotype 1 infection in a majority of patients who had previously not ...


Google News